US FDA Approves Roche's Companion Diagnostic for HER2-Targeted Ziihera Treatment

US FDA Approves Roche's Companion Diagnostic for HER2-Targeted Ziihera Treatment

By, Admin 27 November 2024

US FDA approves Roche’s companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with Ziihera

Overview

Roche announced the US Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test. This test is now the first and only FDA-approved companion diagnostic to aid in the assessment of HER2-positive status to identify BTC patients who are eligible for treatment with Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii).

About the Receptor: HER2

  • HER2 is a receptor protein expressed in a variety of cancers and serves as a predictive biomarker to help determine if a patient will respond to HER2-targeted therapy. 
  • No approved and validated HER2 test existed to identify eligible BTC patients until the approval of this expanded label for the PATHWAY HER2 (4B5) test.

Words from the Roche Diagnostics

  • This test is a step forward in furthering access to personalised medicine,"" said Jill German, Head of Pathology Lab at Roche Diagnostics. 
  • The prognosis for patients diagnosed with BTC is poor, as very few treatment options exist. Now, these patients have access to the first standardised test that could make them eligible for targeted therapy, potentially improving clinical outcomes.

Ziihera is the first FDA-approved treatment for adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer.

Biliary Tract Cancer

  • BTC accounts for 3% of all gastrointestinal cancers in the US. Prognosis is poor because of a lack of adequate early detection tools, challenging anatomical access, aggressive tumour biology, and only modest benefit from systemic treatments. 
  • With most cases diagnosed at an advanced stage, the five-year overall survival rate for all BTC cases is 19% for disease that is localised to the original tumour site, and just 3% for cancer that has spread to other areas.

CVR Payment Uncertainty

  • The PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody delivers timely, clear and reliable results, enabling therapeutic decisions that can lead to better outcomes for patients. 
  • Already indicated as an aid to identify breast cancer patients eligible for HER2-targeted treatment with Herceptin, Kadcyla, or Enhertu, the test is used in combination with the fully automated Ventana BenchMark slide staining instrument. 
  • The introduction of the new indication for BTC represents a significant expansion of the test's clinical utility. 
  • The assay forms an important part of Roche's comprehensive gastrointestinal cancer solutions portfolio, which is aimed at driving diagnostic certainty for life-changing decisions in cancer care.

About the Assay

  • The assay standardises all immunohistochemistry (IHC) processes from baking through staining, and reduces the possibility of human error. 
  • It also minimises inherent variability resulting from individual reagent dilution and other processes found in manual and semi-automated IHC methods. 
  • The Roche HER2 (4B5) clone achieves consistently high proficiency assessment scores compared to other clones and demonstrates high concordance with HER2 FISH, empowering laboratories to employ the most widely adopted and reliable HER2 IHC primary antibody.

About the Company: Roche

  • Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. 
  • The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!